Phreesia (NYSE:PHR) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Phreesia (NYSE:PHR) from a buy rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

A number of other brokerages also recently issued reports on PHR. Wells Fargo & Company upped their price objective on Phreesia from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Thursday. Royal Bank Of Canada reiterated an “outperform” rating and set a $19.00 target price on shares of Phreesia in a research note on Thursday. Weiss Ratings raised shares of Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Robert W. Baird increased their price target on shares of Phreesia from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Barclays restated an “equal weight” rating and set a $10.00 price objective (down from $24.00) on shares of Phreesia in a report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Phreesia currently has a consensus rating of “Hold” and a consensus price target of $15.25.

Phreesia Price Performance

Shares of NYSE PHR opened at $10.97 on Friday. Phreesia has a twelve month low of $7.77 and a twelve month high of $30.43. The stock’s 50 day moving average price is $11.25 and its 200-day moving average price is $10.47. The company has a market capitalization of $678.06 million, a PE ratio of 64.53 and a beta of 0.86. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.41.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.06). The business had revenue of $129.46 million for the quarter, compared to analysts’ expectations of $129.06 million. Phreesia had a net margin of 2.06% and a return on equity of 5.35%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.01 earnings per share. On average, equities analysts anticipate that Phreesia will post 0.38 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Several large investors have recently added to or reduced their stakes in the company. Pale Fire Capital SE lifted its holdings in Phreesia by 3.2% during the second quarter. Pale Fire Capital SE now owns 8,924,329 shares of the company’s stock valued at $91,831,000 after purchasing an additional 275,000 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Phreesia in the second quarter worth about $72,234,000. Vanguard Group Inc. increased its stake in shares of Phreesia by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock worth $97,194,000 after purchasing an additional 39,540 shares in the last quarter. Granahan Investment Management LLC raised its position in shares of Phreesia by 73.8% in the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after purchasing an additional 1,018,987 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Phreesia by 28.8% in the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after purchasing an additional 446,890 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.